Ratings HAEMATO AG Xetra

Equities

End-of-day quote Xetra Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
26.2 ^EUR	-0.76%		-1.50%	-5.76%

2021	HAEMATO AG Proposes Dividend Payment	CI
2021	HAEMATO AG Provides Earnings Guidance for the Year 2021	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.34 for the 2023 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
This company will be of major interest to investors in search of a high dividend stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HAEMATO AG	-5.76%	119M		-
MERCK KGAA	+5.31%	70.44B		A
KYOWA KIRIN CO. LTD.	+10.97%	8.94B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B		-
YUHAN CORPORATION	+3.20%	3.85B		B-
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B		C-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B	-	-
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality